Published in Ann Neurol on October 01, 1994
Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol (1999) 2.07
Chemokine expression in simian immunodeficiency virus-induced AIDS encephalitis. Am J Pathol (1996) 1.67
Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol (2003) 1.62
Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis (2008) 1.56
Human immunodeficiency virus encephalitis in SCID mice. Am J Pathol (1996) 1.55
MiR-21 in Extracellular Vesicles Leads to Neurotoxicity via TLR7 Signaling in SIV Neurological Disease. PLoS Pathog (2015) 1.50
Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism. J Virol (1996) 1.47
Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Invest (1996) 1.40
The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One (2012) 1.27
YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol (2008) 1.23
Human immunodeficiency virus neurotropism: an analysis of viral replication and cytopathicity for divergent strains in monocytes and microglia. J Virol (1998) 1.22
Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr (2013) 1.21
Chemokine receptor expression on resident and inflammatory cells in the brain of macaques with simian immunodeficiency virus encephalitis. Am J Pathol (1998) 1.18
Cell cycle proteins exhibit altered expression patterns in lentiviral-associated encephalitis. J Neurosci (2002) 1.17
Molecular targets of opiate drug abuse in neuroAIDS. Neurotox Res (2005) 1.16
Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains. J Virol (2000) 1.14
Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis. J Neuroimmune Pharmacol (2012) 1.08
Macrophages relate presynaptic and postsynaptic damage in simian immunodeficiency virus encephalitis. Am J Pathol (2002) 1.07
Pathogenic and protective correlates of T cell proliferation in AIDS. HNRC Group. HIV Neurobehavioral Research Center. J Clin Invest (1996) 1.07
Longitudinal analysis of monocyte/macrophage infection in simian immunodeficiency virus-infected, CD8+ T-cell-depleted macaques that develop lentiviral encephalitis. Am J Pathol (2006) 1.06
Induction of cell-cycle regulators in simian immunodeficiency virus encephalitis. Am J Pathol (2000) 1.05
Molecular pathology of neuro-AIDS (CNS-HIV). Int J Mol Sci (2009) 1.04
Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects. J Virol (2008) 1.02
Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer. J Neurovirol (2013) 0.99
Shedding of PECAM-1 during HIV infection: a potential role for soluble PECAM-1 in the pathogenesis of NeuroAIDS. J Leukoc Biol (2006) 0.99
HIV-1 Tat alters neuronal autophagy by modulating autophagosome fusion to the lysosome: implications for HIV-associated neurocognitive disorders. J Neurosci (2015) 0.96
Up-regulation of microRNA-142 in simian immunodeficiency virus encephalitis leads to repression of sirtuin1. FASEB J (2013) 0.96
Rate and severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS. Mol Med (1999) 0.94
Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. J Neuroimmune Pharmacol (2009) 0.94
HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS (2014) 0.92
Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS. J Neurovirol (2008) 0.91
Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp Neurol (2007) 0.89
4-Aminopyridine improves spatial memory in a murine model of HIV-1 encephalitis. J Neuroimmune Pharmacol (2009) 0.89
Characterization of cell death pathways in human immunodeficiency virus-associated encephalitis. Am J Pathol (2005) 0.85
Persistent hijacking of brain proteasomes in HIV-associated dementia. Am J Pathol (2009) 0.85
Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders. J Neuroimmune Pharmacol (2014) 0.84
Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. J Neuroinflammation (2004) 0.83
Mononuclear phagocyte hydrolytic enzyme activity associated with cerebral HIV-1 infection. Am J Pathol (1997) 0.83
Synaptic dysfunction in human immunodeficiency virus type-1-positive subjects: inflammation or impaired neuronal plasticity? J Intern Med (2013) 0.83
Bone marrow diffusion measures correlate with dementia severity in HIV patients. AJNR Am J Neuroradiol (2006) 0.83
HIV leucoencephalopathy and TNFalpha expression in neurones. J Neurol Neurosurg Psychiatry (2005) 0.82
Genetic variation and HIV-associated neurologic disease. Adv Virus Res (2013) 0.81
When human immunodeficiency virus meets chemokines and microglia: neuroprotection or neurodegeneration? J Neuroimmune Pharmacol (2012) 0.81
The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model. J Interferon Cytokine Res (2014) 0.80
Enhancement of NMDA receptor-mediated excitatory postsynaptic currents by gp120-treated macrophages: implications for HIV-1-associated neuropathology. J Neuroimmune Pharmacol (2013) 0.80
Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders. Curr HIV Res (2015) 0.79
In vivo modeling of HIV-1 mediated neurodegeneration. Am J Pathol (1996) 0.78
Human immunodeficiency virus and its effects on the visual system. Infect Dis Rep (2012) 0.77
The HIV Protein gp120 Alters Mitochondrial Dynamics in Neurons. Neurotox Res (2016) 0.77
Synaptic Plasticity and Neurological Disorders in Neurotropic Viral Infections. Neural Plast (2015) 0.75
Brain and liver pathology, amyloid deposition, and interferon responses among older HIV-positive patients in the late HAART era. BMC Infect Dis (2017) 0.75
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol (2009) 1.75
Mössbauer studies of alkane omega-hydroxylase: evidence for a diiron cluster in an integral-membrane enzyme. Proc Natl Acad Sci U S A (1997) 1.67
Recombinant toluene-4-monooxygenase: catalytic and Mössbauer studies of the purified diiron and rieske components of a four-protein complex. Biochemistry (1996) 1.56
Mössbauer studies of the formation and reactivity of a quasi-stable peroxo intermediate of stearoyl-acyl carrier protein Delta 9-desaturase. Biochemistry (1999) 1.29
Reduced mono-, di-, and tetracubane-type clusters containing the [MoFe3S4]2+ core stabilized by tertiary phosphine ligation. Inorg Chem (2000) 0.96
Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol (1997) 0.93
Molybdenum-iron-sulfur clusters of nuclearities eight and sixteen, including a topological analogue of the P-cluster of nitrogenase. Inorg Chem (2001) 0.90
Mössbauer, EPR, and MCD studies of the C9S and C42S variants of Clostridium pasteurianum rubredoxin and MDC studies of the wild-type protein. J Biol Inorg Chem (2000) 0.89
Assembly of a [2Fe-2S]2+ cluster in a molecular variant of Clostridium pasteurianum rubredoxin. Biochemistry (1997) 0.83
Pathogenesis of HIV encephalitis. Acta Pathol Jpn (1991) 0.77
Herpes simplex virus brainstem encephalitis in an AIDS patient. Clin Neuropathol (1995) 0.76
Limited brain access for leptin in obesity. Pituitary (2002) 0.76
Cellular therapies for neurodegenerative diseases. Clin Neurosurg (2001) 0.75